The acute coronary syndrome sub-segment under application segment is projected to dominate the global cardiac biomarkers market during the forecast period. It is likely to occur due to a rise in the investment by various health institutes in biomarker testing for early detection of the disease. This information is given in an upcoming report by Fortune Business Insights, titled, “Cardiac Biomarkers Market Size, Share and Global Trend By Type (Troponin, Creatine kinase-MB (CK-MB), B-type Natriuretic Peptide (BNP), and N-terminal pro b-type natriuretic peptide (NT-proBNP), Myoglobin), By Application (Acute Coronary Syndrome, Myocardial Infarction, Congestive Heart Failure), By End User (Hospitals, Diagnostic Centers, Homecare Settings) and Geography Forecast till 2026.”
For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/cardiac-biomarkers-market-101233
Fortune Business Insights has further profiled some of the prominent market players operating in the global cardiac biomarkers market. They are as follows:
Thermo Fisher Scientific
Abbott
Becton
Bio-Rad Laboratories, Inc.
Hoffmann-La Roche Ltd.
Randox Laboratories Ltd.
Beckman Coulter, Inc.
Dickinson and Company
Dickinson and Company
bioMérieux SA
Other key market players
Global Cardiac Biomarkers Market Segmentation
By Type
Troponin
Creatine kinase-MB (CK-MB)
B-type Natriuretic Peptide (BNP), and N-terminal pro b-type natriuretic peptide (NT-proBNP)
Myoglobin
Others
By Application
Acute Coronary Syndrome
Myocardial Infarction
Congestive Heart Failure
Others
By End User
Hospitals
Diagnostic Centers
Homecare Settings
Others
By Geography
North America (USA and Canada)
Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
Latin America (Brazil, Mexico and Rest of Latin America)
Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)